Sandoz launches authorized Pataday generic
PRINCETON, N.J. — Novartis’ Sandoz division on Monday announced the introduction of its authorized generic of Alcon’s Pataday (olopatadine hydrochloride ophthalmic Solution, 0.2%).
“As a division of Novartis, we are pleased to have the opportunity to further drive access to this critical medicine in the U.S. market,” Sandoz president Peter Goldschmidt said. “By working internally with the Novartis group, Sandoz is able to deliver a wide range of ophthalmic dosage forms that require high technical expertise.”
The solution is indicated to treat ocular itching associated with allergic conjunctivitis. The drug saw U.S. sales of $293 million for the 12 months ended April 2017, according to QuintilesIMS data.